'Lipodystrophy syndrome' in the setting of HIV infection has come to encomp
ass a collection of morphological and metabolic abnormalities linked with t
he use of antiretroviral therapy and other risk factors. We review the clin
ical literature on this subject as it has evolved historically, taking pert
inent methodological issues into account.